EBMT 2020 | Current treatment landscape of DLBCL
Edmund Waller
• 23 Aug 2020
Edmund Waller, MD, PhD, FACP, Division of Hematology/Oncology, Emory Clinic, Atlanta, GA, explores the current treatment landscape of diffuse large B-cell lymphoma (DLBCL), and discusses future approaches being developed, including earlier infusion of CAR T-cell therapies as evaluated in the BELINDA (NCT03570892) and TRANSFORM (NCT03575351) studies. Dr Waller also discusses polatuzumab vedotin, an antibody-drug conjugate that displays increased remission rates in relapsed/refractory lymphoma patients when compared to salvage bendamustine/rituximab. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
